Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 16/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.47 |
| ▸ | UBE2M | P61081 | 1/20 | 0.47 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4236025 | 0.86 | ALDH1A1 (0.53) | EPHX2UBE2MDCUN1D1KMT2AMAPT | |
| SCHEMBL4243366 | 0.86 | ALDH1A1 (0.53) | EPHX2UBE2MDCUN1D1KMT2AMAPT | |
| SCHEMBL4244477 | 0.85 | EPHX2 (0.49) | EPHX2UBE2MDCUN1D1 | |
| SCHEMBL4238867 | 0.84 | MAPT (0.62) | MAPT | |
| SCHEMBL4242742 | 0.83 | UBE2M (0.46) | EPHX2EPHX1UBE2MDCUN1D1 | |
| SCHEMBL4244419 | 0.82 | ALDH1A1 (0.42) | MAPT | |
| SCHEMBL4240584 | 0.82 | CCR5 (0.42) | EPHX2UBE2MDCUN1D1KMT2AMEN1 | |
| SCHEMBL4247940 | 0.82 | POLB (0.52) | EPHX2UBE2MDCUN1D1MAPT | |
| SCHEMBL4249067 | 0.80 | EPHX2 (0.46) | EPHX2EPHX1UBE2MDCUN1D1 | |
| SCHEMBL4249075 | 0.80 | EPHX2 (0.46) | EPHX2EPHX1UBE2MDCUN1D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7491735-B2 | Chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2009-02-17 | — | — | US | disclosed |
| US-20050277670-A1 | Chemokine receptor binding compounds | ANORMED INC. | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277670-A1 | Chemokine receptor binding compounds | CCR5, CXCR3, CCL5 | EPHX2 1935/4885EPHX1 1384/4885UBE2M 4562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.